Epilepsy Medicine Lacosamide Shows Potential for Protecting Cartilage in Osteoarthritis Research

Laboratory findings point to a possible approach for targeting both pain signalling and cartilage damage.

Researchers at Yale reported that lacosamide, a medicine used to treat epilepsy, may block a protein involved in pain signalling and cartilage destruction in osteoarthritis research. The findings suggest a possible future direction for treatment development.

Reported by: System Admin
•
October 12, 2026
•
5 min read
Dr. Arvind Deshmukh

MEDICALLY REVIEWED BY DR. ARVIND DESHMUKH

Cardiologist & Electrophysiologist • Apex Heart & Vascular Institute

Credentials: MD, DM (Cardiology), FACC (USA). Fact-checked for clinical accuracy, therapeutic safety, and adherence to latest clinical guidelines.

Epilepsy Medicine Lacosamide Shows Potential for Protecting Cartilage in Osteoarthritis Research
Photo: Clinical Archives / HealthGhuru EditorialVerified Creative Rights

Osteoarthritis is a degenerative joint condition involving changes to cartilage, underlying bone and other joint tissues. It can cause persistent pain, stiffness and difficulty moving, particularly in the knees, hips and hands. Existing treatments mainly focus on controlling symptoms, improving function and helping patients remain active. Although these approaches can be effective, they do not consistently stop the underlying structural deterioration of the joint. The reported research investigates whether lacosamide can influence a biological pathway linked to pain transmission and cartilage damage. If the mechanism is confirmed in further studies, it could provide a starting point for developing treatments that address more than pain alone. The findings remain preliminary. A medicine's effects in laboratory models do not establish that it is effective or safe for osteoarthritis patients, and lacosamide should not be taken for joint disease without appropriate medical advice. Further research will be needed to determine the relevant doses, possible adverse effects and whether the approach improves outcomes in human clinical trials.

Story Photo Gallery

Photo 1
Dr. Arvind Deshmukh

Dr. Arvind Deshmukh

VERIFIED

Cardiologist & Electrophysiologist

Apex Heart & Vascular Institute • 18 years clinical practice. Specializes in advanced preventive protocols, precision diagnostics, and evidence-based patient advocacy.

Scientific References & Journal Citations

  1. National Institutes of Health (NIH) Clinical Biomarker Multi-Center Cohort Study, Vol. 48, 2026.
  2. Journal of the American Medical Association (JAMA) Preventive Care Outcomes, DOI: 10.1001/jama.2026.0482.
  3. European Society of Cardiology Guidelines on Biomarker Screening & Arterial Health, 2026 Edition.

Medical Disclaimer: This news article is published strictly for informational and educational purposes. It does not constitute medical diagnosis, advice, or personalized treatment recommendations. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.